Compare Sanofi SA (SNY) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vanguard Ultra Short Bond ETF — how do they compare? Sanofi SA trades at $43.12 (market cap $104.06B), while Vanguard Ultra Short Bond ETF trades at $49.6. The key difference: Sanofi SA pays a 5.61% dividend while Vanguard Ultra Short Bond ETF pays none. Which is the better fit depends on your goals.
| SNY | VUSB | |
|---|---|---|
Market Cap | $104.06B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $52.34 | $50.03 |
52-Week Low | $41.33 | $49.55 |
Enterprise Value | $124.09B | — |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
VUSB trades at $49.595 with minimal daily movement, showing a slight decline of 0.01%. The technical picture is bearish with moving averages signaling selling pressure, though oscillators suggest potential short-term recovery. Recent dividend distributions of $0.17-0.18 per share demonstrate consistent income generation. Market sentiment is influenced by Federal Reserve interest rate expectations favoring short-term bonds.
The outlook remains cautious with bearish technical indicators offset by positive sentiment around short-term bond strategies. Investment opportunity lies in the ETF's defensive positioning amid potential rate hikes, while risks include interest rate sensitivity and market volatility. The stock presents a conservative income play in uncertain monetary policy environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
